1. Bilayered skin equivalent mimicking psoriasis as predictive tool for preclinical treatment studies.
- Author
-
Morgner B, Werz O, Wiegand C, and Tittelbach J
- Subjects
- Humans, Dexamethasone pharmacology, Dexamethasone administration & dosage, Adalimumab therapeutic use, Adalimumab administration & dosage, Adalimumab pharmacology, Cytokines metabolism, Cytokines genetics, Pentacyclic Triterpenes, Keratinocytes metabolism, Keratinocytes drug effects, Cell Differentiation drug effects, Antimicrobial Cationic Peptides metabolism, Antimicrobial Cationic Peptides genetics, Organoids drug effects, Organoids pathology, Interleukin-17 metabolism, Interleukin-17 genetics, Psoriasis drug therapy, Psoriasis genetics, Psoriasis pathology, Skin metabolism, Skin drug effects, Skin pathology, Anti-Inflammatory Agents pharmacology, Anti-Inflammatory Agents administration & dosage
- Abstract
Psoriasis is a prevalent, inflammatory skin disease without cure. Further research is required to unravel dysregulated processes and develop new therapeutic interventions. The lack of suitable in vivo and in vitro preclinical models is an impediment in the psoriasis research. Recently, the development of 3D skin models has progressed including replicas with disease-like features. To investigate the use of in vitro models as preclinical test tools, the study focused on treatment responses of 3D skin replicas. Cytokine-priming of skin organoids induced psoriatic features like inflammation, antimicrobial peptides (AMP), hyperproliferation and impaired differentiation. Topical application of dexamethasone (DEX) or celastrol (CEL), a natural anti-inflammatory compound reduced the secretion of pro-inflammatory cytokines. DEX and CEL decreased the gene expression of inflammatory mediators. DEX barely affected the psoriatic AMP transcription but CEL downregulated psoriasis-driven AMP genes. Subcutaneous application of adalimumab (ADM) or bimekizumab (BMM) showed anti-psoriatic effects via protein induction of the differentiation marker keratin-10. Dual blockage of TNF-α and IL-17A repressed the inflammatory psoriasis phenotype. BMM inhibited the psoriatic expression of AMP genes and induced KRT10 and cell-cell contact genes. The present in vitro model provides a 3D environment with in vivo-like cutaneous responses and represents a promising tool for preclinical investigations., Competing Interests: Competing interests The authors declare no competing interests., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF